Acute Pain Therapeutics
1. Olinvyk patent expiration
Treatment: Management of acute pain by intravenous injection
OLINVYK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US11931350 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: 30 October, 2024
Market Authorisation Date: 30 October, 2020
Dosage: SOLUTION
More Information on Dosage
OLINVYK family patents
2. Vioxx patent expiration
Treatment: Relief of the signs and symptoms of osteoarthritis; Relief of the signs and symptoms of rheumatoid arthritis in adults; Management of acute pain
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5691374 | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May, 2015
(10 years ago) | |
|
US5474995 (Pediatric) | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Dec, 2013
(12 years ago) | |
|
US6239173 (Pediatric) | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec, 2013
(12 years ago) | |
|
US5691374 (Pediatric) | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov, 2015
(10 years ago) | |
| US5474995 | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Jun, 2013
(12 years ago) | |
|
US6063811 (Pediatric) | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov, 2017
(8 years ago) | |
| US6239173 | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun, 2013
(12 years ago) | |
| US6063811 | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May, 2017
(8 years ago) | |
Drugs and Companies using ROFECOXIB ingredient
Market Authorisation Date: 20 May, 1999
Dosage: TABLET; SUSPENSION
How can I launch a generic of VIOXX before it's drug patent expiration?
More Information on Dosage
VIOXX family patents